ATE399203T1 - Varianten des wachstumsfaktors der vaskulären endothelzellen, ihre verwendung sowie methoden für ihre herstellung - Google Patents

Varianten des wachstumsfaktors der vaskulären endothelzellen, ihre verwendung sowie methoden für ihre herstellung

Info

Publication number
ATE399203T1
ATE399203T1 AT96929012T AT96929012T ATE399203T1 AT E399203 T1 ATE399203 T1 AT E399203T1 AT 96929012 T AT96929012 T AT 96929012T AT 96929012 T AT96929012 T AT 96929012T AT E399203 T1 ATE399203 T1 AT E399203T1
Authority
AT
Austria
Prior art keywords
variants
growth factor
vascular endothelial
vegf
production
Prior art date
Application number
AT96929012T
Other languages
English (en)
Inventor
Bruce Keyt
Francis Nguyen
Napoleone Ferrara
Brian Cunningham
James Wells
Bing Li
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE399203T1 publication Critical patent/ATE399203T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT96929012T 1995-08-25 1996-08-23 Varianten des wachstumsfaktors der vaskulären endothelzellen, ihre verwendung sowie methoden für ihre herstellung ATE399203T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US282795P 1995-08-25 1995-08-25
US08/567,200 US6020473A (en) 1995-08-25 1995-12-05 Nucleic acids encoding variants of vascular endothelial cell growth factor
US08/691,794 US6057428A (en) 1995-08-25 1996-08-02 Variants of vascular endothelial cell growth factor

Publications (1)

Publication Number Publication Date
ATE399203T1 true ATE399203T1 (de) 2008-07-15

Family

ID=26670933

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96929012T ATE399203T1 (de) 1995-08-25 1996-08-23 Varianten des wachstumsfaktors der vaskulären endothelzellen, ihre verwendung sowie methoden für ihre herstellung

Country Status (10)

Country Link
US (4) US6020473A (de)
EP (1) EP0851920B1 (de)
JP (1) JP3456706B2 (de)
AT (1) ATE399203T1 (de)
AU (1) AU6857296A (de)
CA (1) CA2230144C (de)
DE (1) DE69637570D1 (de)
DK (1) DK0851920T3 (de)
ES (1) ES2309990T3 (de)
WO (1) WO1997008313A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005505B1 (en) * 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US5728541A (en) * 1996-07-12 1998-03-17 Precision Therapeutics, Inc. Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays
US20040072722A1 (en) 2002-10-10 2004-04-15 Kornblith Paul L. Methods for assessing efficacy of chemotherapeutic agents
US20040023375A1 (en) * 2002-07-30 2004-02-05 Precision Therapeutics, Inc. Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
US6416967B2 (en) * 1996-07-12 2002-07-09 Precision Therapeutics, Inc. Method of using multicellular particulates to analyze malignant or hyperproliferative tissue
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
US6635421B1 (en) 1997-12-09 2003-10-21 Children's Medical Center Corporation Neuropilins and use thereof in methods for diagnosis and prognosis of cancer
WO1999029861A1 (en) * 1997-12-09 1999-06-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
US6777534B1 (en) 1997-12-09 2004-08-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
CN1295617A (zh) 1998-02-06 2001-05-16 科莱特诺医疗公司 血管生成因子－血管内皮细胞生长因子vegf的突变体
US7090834B1 (en) * 1999-04-16 2006-08-15 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof
IL145675A0 (en) * 1999-04-16 2002-06-30 Genentech Inc Vascular endothelial cell growth factor variants and uses thereof
AU2004202596B2 (en) * 1999-04-16 2007-06-14 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
EP1179541B1 (de) 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Zusammensetzungen und Verfahren zur Krebsbehandlung durch die selektive Hemmung von VEGF
US6475796B1 (en) * 1999-05-20 2002-11-05 Scios, Inc. Vascular endothelial growth factor variants
AR025984A1 (es) * 1999-10-07 2002-12-26 Maxygen Aps Polipeptidos oligomericos de cadena simple
JP2003513105A (ja) * 1999-11-02 2003-04-08 ジェネンテック・インコーポレーテッド ｅＮＯＳ活性の調節とその治療的使用
US7078382B1 (en) * 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
WO2001053345A1 (en) * 2000-01-20 2001-07-26 North Bristol Nhs Trust Vegf148 isoform, a truncated splice variant of vegf. vegf heterodimers and therapeutical uses thereof
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
US20020068694A1 (en) * 2000-07-26 2002-06-06 Jeltsch Markku Michael Glycosylated VEGF-B and method for increasing the amount of soluble VEGF-B
KR100419972B1 (ko) * 2000-09-09 2004-03-03 굿젠 주식회사 링커 염기서열로 연결된 인간 ｖｅｇｆ의 돌연변이형동형이합체 유전자, 이를 포함하는 발현벡터, 이의형질전환체 및 단백질
AU2001296521A1 (en) * 2000-10-02 2002-04-15 St. Elizabeth's Medical Center Of Boston, Inc. Use of lymphangiogenic agents to treat lymphatic disorders
WO2002081520A2 (en) * 2001-04-06 2002-10-17 Maxygen Holdings Ltd. Single chain dimeric polypeptides derived from the vegf family
JPWO2002100441A1 (ja) * 2001-06-08 2004-09-24 株式会社ディナベック研究所 血管再生療法
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
JP4303105B2 (ja) * 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
US20100234570A1 (en) * 2001-06-28 2010-09-16 Domantis Limited Ligand
AU2002322461B2 (en) * 2001-07-12 2007-12-06 Vegenics Limited Lymphatic endothelial cells materials and methods
WO2003022874A1 (fr) * 2001-09-12 2003-03-20 Beijing Institute For Cancer Research Peptides antagonistes du recepteur flt-1 du vegr
US20040086888A1 (en) * 2001-10-18 2004-05-06 Kornblith Paul L Method for tandem genomic/proteomic analysis of proliferating cells
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
EP1342783A1 (de) * 2002-03-08 2003-09-10 Eming, Sabine, A.,Dr. med. Proteolyseresistenter aktiver VEGF
IL165392A0 (en) * 2002-06-05 2006-01-15 Genentech Inc Compositions and methods for liver growth and liver protection
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
CA2511910A1 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
CN102225194B (zh) 2003-03-12 2014-07-16 健泰科生物技术公司 Bv8和/或EG-VEGF促进造血的用途
JP2005110508A (ja) * 2003-10-02 2005-04-28 Nec Soft Ltd 血管内皮増殖因子受容体２型に対する特異的結合性を有するヘビ毒由来血管内皮増殖因子様タンパク質と用途
CN1304427C (zh) * 2004-06-08 2007-03-14 成都康弘生物科技有限公司 抑制血管新生的融合蛋白质及其用途
ES2381014T3 (es) * 2004-06-08 2012-05-22 Chengdu Kanghong Biotechnologies Co., Ltd. Proteína quimérica inhibidora de la angiogénesis y el uso
JP2008501724A (ja) * 2004-06-11 2008-01-24 ヴィクトリアン ティッシュ エンジニアリング センター プロプライアトリー リミテッド 組織材料およびマトリックス
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
MX2007001589A (es) * 2004-08-09 2007-08-02 Alios Biopharma Inc Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
AU2006287175A1 (en) * 2005-09-01 2007-03-08 Precision Therapeutics, Inc. Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics
TW200732347A (en) * 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
CA2632866A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
KR20080108570A (ko) * 2006-03-27 2008-12-15 제넨테크, 인크. 신장 질환을 치료하는 방법
AU2013221919B2 (en) * 2006-10-04 2016-04-14 Genentech, Inc. ELISA for VEGF
DK2457929T3 (en) 2006-10-04 2016-09-05 Genentech Inc Elisa vegf
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CA2683801A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
EP2310507A4 (de) 2008-07-08 2013-03-20 David Gladstone Inst Verfahren und zusammensetzungen zur angiogenesemodulierung
US8741839B2 (en) * 2009-01-18 2014-06-03 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrin
NZ605449A (en) 2010-07-09 2015-03-27 Genentech Inc Anti-neuropilin antibodies and methods of use
US10457713B2 (en) 2012-07-30 2019-10-29 Trophogen, Inc. Glycoprotein hormone long-acting superagonists
JP6429774B2 (ja) 2012-07-30 2018-11-28 トロホジェン・インコーポレーテッド 糖タンパク質ホルモン長期作用性スーパーアゴニスト
KR20160101906A (ko) 2013-11-05 2016-08-26 트로포젠 인코포레이티드 당단백질 호르몬의 장시간-작용하는 초작용제
KR20170098876A (ko) * 2015-01-16 2017-08-30 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Vegf 변이체 폴리펩타이드 조성물
EP3216458A1 (de) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modifizierter vaskulärer endothelialen wachstumsfaktor a (vegf-a) und dessen medizinische verwendung
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) * 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) * 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) * 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) * 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) * 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
NZ201918A (en) * 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
HUT35524A (en) * 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3413608A1 (de) * 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
IL74909A (en) * 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
JPS63502716A (ja) * 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
EP0266032A1 (de) * 1986-08-29 1988-05-04 Beecham Group Plc Modifiziertes fibrinolytisches Enzym
US5073492A (en) * 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
DE69229454T2 (de) * 1991-03-28 2000-01-05 Merck & Co., Inc. Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
DE9104598U1 (de) 1991-04-16 1992-10-01 Natec Reich, Summer GmbH & Co KG, 8996 Opfenbach Schälmaschine
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
IL145675A0 (en) * 1999-04-16 2002-06-30 Genentech Inc Vascular endothelial cell growth factor variants and uses thereof
US7090834B1 (en) * 1999-04-16 2006-08-15 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof

Also Published As

Publication number Publication date
WO1997008313A1 (en) 1997-03-06
US6057428A (en) 2000-05-02
US6020473A (en) 2000-02-01
US20060024785A1 (en) 2006-02-02
CA2230144A1 (en) 1997-03-06
EP0851920B1 (de) 2008-06-25
AU6857296A (en) 1997-03-19
US7427596B2 (en) 2008-09-23
ES2309990T3 (es) 2008-12-16
DE69637570D1 (de) 2008-08-07
JPH10511557A (ja) 1998-11-10
EP0851920A1 (de) 1998-07-08
JP3456706B2 (ja) 2003-10-14
DK0851920T3 (da) 2008-09-22
CA2230144C (en) 2013-02-12
US20070082847A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
DE69637570D1 (de) Varianten des wachstumsfaktors der vaskulären endothelzellen, ihre verwendung sowie methoden für ihre herstellung
ATE377081T1 (de) Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
ATE182148T1 (de) Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
ATE317226T1 (de) Behandlung der schizophrenie mit ampakinen und neuroleptika
ATE286126T1 (de) Glialmitogene faktoren, ihre herstellung und verwendung
DE69842174D1 (de) Verfahren zur Herstellung humanisierter Antikörper durch randomisierte Mutagenese
CY1112101T1 (el) Νευροτροφικοι παραγοντες
DE60031419D1 (de) Zusammensetzungen und verfahren für verbesserte zellkultur
UA105625C2 (uk) Пастка vegf і її терапевтичне застосування
BR9508402A (pt) Ligante de união construção de fator de tecido composição farmacêutica kit e uso de um ligante de união
DK0817648T3 (da) Antagonister mod vaskulære endotelcellevækstfaktorer
DK0892849T3 (da) Fremgangsmåde til anvendelse af obese-genet og dets genprodukt til stimulering af hæmatopoietisk udvikling
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
DE60028565D1 (de) Vaskuläre endothelzellen wachstumsfaktor (vegf) varianten und dessen verwendungen
ATE330003T1 (de) Rekombinanter stabiler zellklon, seine herstellung und verwendung
NO20004502D0 (no) Nye sammensetninger av eprosartan
ES2192199T3 (es) Ligandos de la familia eph biologicamente activos.
AU1218202A (en) Receptor in the ED<sub>b</sub> fibronectin domain
DE50003001D1 (de) Verwendung von porphyrinderivaten in aquarien
DE69935785D1 (de) Substitutierte aminosaeuren als erythropoietin-mimetica
ATE432292T1 (de) Antitumorantikörper, proteine und deren verwendung
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
TR200102502T2 (tr) Trombin reseptör modülatörleri olarak yararlı sübstitüe edilmiş heterosiklik açil-tripeptidler.
DE60011785D1 (de) Verfahren zur herstellung von proteinen in wirtszellen unter verwendung von chaperoninen
ATE305042T1 (de) Globale regulatoren von pathogenen bakteriellen genen; bakterielles selbstinduzierendes inaktivierungsprotein, die als ziele für die herstellung von krankheitsresistenzen einsetzbar sind

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties